Clinical trials: Drug Eluting Stents
Coronary Artery Diseases
BIOTRONIK - BIOFLOW-III Registry French Satellite
For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success.
- Trial name
- NCT02273648
- Testing
- Drug Eluting Stent (DES)
- Where
- 50 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Biotronik France
Chronic Total Occlusion of Coronary Artery, Vascular Disease
XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Conditions
- Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
- Trial name
- XVU-AV DAPT (NCT01106534)
- Testing
- clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
- Where
- 144 sites in United States
- Volunteers
- 870 people
- Sponsor
- Abbott Medical Devices
Coronary Stent Restenosis
Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis
The aim of this open label, randomized study is to compare the safety and efficacy of three different methods to handle coronary drug eluting stent (DES) in-stent restenosis (ISR).
- Trial name
- OPEN-ISR (NCT04862052)
- Testing
- Intravascular management of prior implanted coronary drug eluting stent restenosis
- Where
- 2 sites in Hungary
- Volunteers
- 108 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Coronary Artery Disease
TAXUS PERSEUS Workhorse
The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo…
- Trial name
- PERSEUS WH (NCT00484315)
- Testing
- Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
- Where
- 90 sites in United States, Australia and 2 more
- Volunteers
- 1,264 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Coronary Stenting and Coronary Bypass Grafting at the Same Time in a Specialty Built Operating Room
This study will combine coronary stenting with minimally invasive robotic coronary bypass surgery, accomplished with the use of the da Vinci robot, to restore blood flow to occluded coronary arteries.
- Trial name
- NCT00366015
- Testing
- Robotic-assisted Coronary Surgical Revascularization, PCI- Drug Eluting Stents
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Coronary Artery Disease, Atherosclerosis, Coronary
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease
- Trial name
- BIOFLOW-V (NCT02389946)
- Testing
- Orsiro DES, Xience DES
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Biotronik, Inc.
Coronary Artery Disease, Myocardial Ischemia
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent
The purpose of this study is to evaluate the safety and feasibility of a new coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle.
- Trial name
- MEND II (NCT02189499)
- Testing
- AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
- Where
- 4 sites in Colombia
- Volunteers
- 42 people
- Sponsor
- Amaranth Medical Inc.
Coronary Heart Disease
Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES)
The purpose of this study is to evaluate the differences of wall shear stress distribution among different types of drug-eluting stents and its impact on vessel healing evaluated by intravascular optical coherence tomography…
- Trial name
- NCT01942044
- Testing
- Promus element, Xience prime, and Nobori
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Kobe University
Coronary Artery Disease (CAD)
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
To determine the efficacy of prasugrel versus clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting…
- Trial name
- TRIGGER-PCI (NCT00910299)
- Testing
- Prasugrel, Clopidogrel
- Where
- 27 sites in United States, Germany
- Volunteers
- 423 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
e-BioMatrix PostMarket Surveillance Registry
The purpose of the e-BioMatrix PMS registry is to capture clinical data of the BioMatrix (Biolimus A9-Eluting) stent system in relation to safety and effectiveness.
- Trial name
- NCT01254487
- Where
- 9 sites in Spain, Switzerland and 1 more
- Volunteers
- 1,121 people
- Sponsor
- Biosensors Europe SA
Drug Eluting Stent, Coronary Artery Disease
CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)
COACT registry is a multicenter registry of consecutive patients undergoing coronary stent implantation at 8 centers in the Catholic University of Korea to evaluate the real world management of patients with coronary artery…
- Conditions
- Drug Eluting Stent, Coronary Artery Disease, Polymorphism, Cholesterol
- Trial name
- COACT (NCT01239914)
- Where
- 8 sites in South Korea
- Volunteers
- 11,719 people
- Sponsor
- The Catholic University of Korea
Myocardial Infarction
Sevoflurane and Percutaneous Coronary Intervention by Stent
Increase in CK-MB after percutaneous coronary angioplasty more than 100% of baseline can represents a problem to the patients resulting in increase of morbidity and mortality.
- Trial name
- NCT02671084
- Testing
- sevoflurane
- Where
- Brazil
- Volunteers
- 701 people
- Sponsor
- Instituto Dante Pazzanese de Cardiologia
Acute Coronary Syndrome
Vascular Healing of DES at 3 Months
The purpose of this study is to compare vascular healing of the stented segment after deployment of new PRO-Kinetic drug eluting stent and Endeavor Resolute zotarolimus-eluting stent in patients with acute coronary syndromes…
- Trial name
- HAT-TRICK-OCT (NCT01391871)
- Testing
- OCT, Transthoracic echocardiography CFR measurement
- Where
- 2 sites in Finland
- Volunteers
- 46 people
- Sponsor
- University of Turku
Coronary Disease
Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)
The purpose of this study is to assess the efficacy of nonpolymer-based rapamycin-eluting stent compared to standard polymer-based paclitaxel-eluting stent to reduce reblockage of coronary arteries.
- Trial name
- NCT00140530
- Testing
- Paclitaxel-eluting stent (Taxus), Rapamycin-eluting stent
- Where
- 2 sites in Germany
- Volunteers
- 450 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease, Stent Restenosis
Matrix Metalloproteinases Expression in the Neointimal Hyperplasia Induced by Drug Eluting Stent (DES) Implantation
If intimal growth is such that the initial lumen is narrowed significantly, distal blood flow is restricted and chronic tissue ischemia results.
- Trial name
- NCT03375528
- Testing
- DES implantation
- Volunteers
- 50 people
- Sponsor
- Dankook University
CHD - Coronary Heart Disease, Angina, Stable
Coronary Microcirculatory and Bioresorbable Vascular Scaffolds
Angina and heart attacks are caused by narrowings in the coronary arteries (blood vessels) supplying the heart. These narrowings can be opened using a balloon and stent (angioplasty).
- Conditions
- CHD - Coronary Heart Disease, Angina, Stable, Myocardial Ischemia
- Trial name
- EMPIRE-BVS (NCT03076476)
- Testing
- Bioresorbable Vascular Scaffolds (BVS), Drug-Eluting Stent (DES) - slow, Drug-Eluting Stent (DES) - standard(std)
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Coronary Stenosis, Coronary Artery Disease
Percutaneous Coronary Intervention (PCI) With Drug-Eluting Stents (DES) Versus Coronary Artery Bypass Graft (CABG) for Patients With Significant Left Main Stenosis
Recent technical advances in percutaneous coronary interventions have made it possible to approach patients with coronary lesions formerly considered to be classical candidates for bypass surgery, e.g.
- Trial name
- NCT00176397
- Testing
- Percutaneous coronary intervention (left main)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University of Leipzig
Coronary Artery Disease, Acute Myocardial Infarction
Drug-coated Balloon Versus Drug-eluting Stent in Acute Myocardial Infarction
Rationale: Compared with balloon angioplasty, implantation of bare metal stents (BMS) and drug eluting stents (DES) have shown to reduce repeat target lesion revascularization in primary percutaneous coronary intervention (PPCI).
- Trial name
- REVELATION (NCT02219802)
- Testing
- Treatment according arm
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- Onze Lieve Vrouwe Gasthuis
Coronary Artery Disease
JACTAX LD Drug Eluting Stent Trial
Prospective, multi-center, randomized trial. A maximum of 130 patients will be enrolled, in a 2:1 ratio to receive either the JACTAX LD stent or the TAXUS™ Libertè™ stent to evaluate the efficacy of the product.
- Trial name
- NCT00754975
- Testing
- JACTAX LD DES, TAXUS™ Libertè™ DES
- Where
- 5 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
COMPARE-II- Vasomotion and Imaging Substudy
The purpose of the study is to compare strut coverage and neointimal thickness between everolimus eluting (XIENCE-V® or PROMUS® stent) and biolimus A9 eluting NOBORI Stent 14 months after stent implantation and to determine the…
- Trial name
- COMPARE-IT (NCT01329237)
- Testing
- dynamic physical exercise and OCT imaging
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Freiburg